Literature DB >> 10847930

Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis?

H Bleichrodt1, J Quiggin.   

Abstract

This paper studies life-cycle preferences over consumption and health status. We show that cost-effectiveness analysis is consistent with cost-benefit analysis if the lifetime utility function is additive over time, multiplicative in the utility of consumption and the utility of health status, and if the utility of consumption is constant over time. We derive the conditions under which the lifetime utility function takes this form, both under expected utility theory and under rank-dependent utility theory, which is currently the most important nonexpected utility theory. If cost-effectiveness analysis is consistent with cost-benefit analysis, it is possible to derive tractable expressions for the willingness to pay for quality-adjusted life-years (QALYs). The willingness to pay for QALYs depends on wealth, remaining life expectancy, health status, and the possibilities for intertemporal substitution of consumption.

Mesh:

Year:  1999        PMID: 10847930     DOI: 10.1016/s0167-6296(99)00014-4

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  29 in total

Review 1.  On individual preferences and aggregation in economic evaluation in healthcare.

Authors:  B Liljas; B Lindgren
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 2.  Utilitarianism and the measurement and aggregation of quality--adjusted life years.

Authors:  P Dolan
Journal:  Health Care Anal       Date:  2001

3.  Efficient use of health care resources: the interaction between improved health and reduced health related income loss.

Authors:  Michael Hoel
Journal:  Int J Health Care Finance Econ       Date:  2002-11

Review 4.  Willingness to pay for a QALY: theoretical and methodological issues.

Authors:  Dorte Gyrd-Hansen
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  A cost-effectiveness analysis of using TheraBite in a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy.

Authors:  Valesca P Retèl; Lisette van der Molen; Lotte M G Steuten; Michiel W van den Brekel; Frans J M Hilgers
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-11       Impact factor: 2.503

6.  The new myth: the social value of the QALY.

Authors:  Werner Brouwer; Job van Exel; Rachel Baker; Cam Donaldson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

7.  The value of a QALY: individual willingness to pay for health gains under risk.

Authors:  Ana Bobinac; Job van Exel; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

8.  The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.

Authors:  Paul A Scuffham; Jennifer A Whitty; Andrew Mitchell; Rosalie Viney
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 9.  Cost-utility and cost-effectiveness studies of telemedicine, electronic, and mobile health systems in the literature: a systematic review.

Authors:  Isabel de la Torre-Díez; Miguel López-Coronado; Cesar Vaca; Jesús Saez Aguado; Carlos de Castro
Journal:  Telemed J E Health       Date:  2014-12-04       Impact factor: 3.536

10.  Life Cycle Analysis and Global Environmental Health Issues.

Authors:  Julia M Gohlke
Journal:  J Health Pollut       Date:  2015-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.